Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Visionary Ventures
Deal Size : $45.0 million
Deal Type : Series B Financing
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures
Details : SYD-101 is designed to be a best-in-class product with maximum efficacy, comfort and 3-year stability at room temperature, all important product attributes when developing drugs for use in children.
Brand Name : SYD-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Visionary Ventures
Deal Size : $45.0 million
Deal Type : Series B Financing
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Santen Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help co...
Brand Name : SYD-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Santen Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?